The windfall from the vaccine – the best-selling pharmaceutical product of all time in a given year – has equipped BioNTech with the funds to push the rest of its experimental pipeline forward. It’s also raised the pressure on the German biotech to show that its growth can be sustained even as its Covid sales wane in coming years.
BioNTech SE raised its forecast for this year’s Covid-19 vaccine sales to as much as 17 billion euros (US$19.7 billion or $26.5 billion), lifting the estimate once more as the pandemic drags on and countries order more shots.
BioNTech and partner Pfizer Inc. have signed contracts to deliver some 2.5 billion doses of the vaccine this year, and expect to manufacture as many as 3 billion doses by year end, the Mainz, Germany-based company said on Tuesday, Nov 9.
